|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Therapy Trials—Drug |
Departments of Surgery (D.A.R., J.A.Q., J.N.R., S.G., J.V., J.H.S., A.W., M.B., S.T.-U., M.L.A., S.J., D.A., K.Z., S.S., C.B., A.H.F., D.D.B., H.S.F.), Neurology (J.A.Q., J.N.R.), Pediatrics (D.A.R., S.G., H.S.F.), Radiology (J.M.P.), Cancer Center Biostatistics (J.E.H., J.M.D.), and Pathology (D.D.B.), Duke University Medical Center, Durham, NC 27710, USA
2 Address correspondence to David A. Reardon, The Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710 (reard003{at}mc.duke.edu).
Abstract
In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus
CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against
malignant glioma (MG). We previously established the maximum tolerated dose of
CPT-11 when administered for 4 consecutive weeks in combination with BCNU
administered on the first day of each 6-week cycle. We now report a phase 2
trial of BCNU plus CPT-11 for patients with MG. In the current study, BCNU
(100 mg/m2) was administered on day 1 of each 6-week cycle. CPT-11
was administered on days 1, 8, 15, and 22 at 225 mg/m2 for patients
receiving CYP3A1- or CYP3A4-inducing anticonvulsants and at 125
mg/m2 for those not on these medications. Newly diagnosed patients
received up to 3 cycles before radiotherapy, while recurrent patients received
up to 8 cycles. The primary end point of this study was radiographic response,
while time to progression and overall survival were also assessed. Seventy-six
patients were treated, including 37 with newly diagnosed tumors and 39 with
recurrent disease. Fifty-six had glioblastoma multiforme, 18 had anaplastic
astrocytoma, and 2 had anaplastic oligodendroglioma. Toxicities (grade 
3)
included infections (13%), thromboses (12%), diarrhea (10%), and neutropenia
(7%). Interstitial pneumonitis developed in 4 patients. Five newly diagnosed
patients (14%; 95% CI, 5%-29%) achieved a radiographic response (1 complete
response and 4 partial responses). Five patients with recurrent MG also
achieved a response (1 complete response and 4 partial responses; 13%; 95% CI,
4%-27%). More than 40% of both newly diagnosed and recurrent patients achieved
stable disease. Median time to progression was 11.3 weeks for recurrent
glioblastoma multiforme patients and 16.9 weeks for recurrent anaplastic
astrocytoma/anaplastic oligodendroglioma patients. We conclude that the
activity of BCNU plus CPT-11 for patients with MG appears comparable to that
of CPT-11 alone and may be more toxic.
References
Aronin, P.A., Mahaley, M.S., Jr., Rudnick, S.A., Dudka, L., Donohue, J.F., Selker, R.G., and Moore, P. (1980) Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: An assessment of risk factors. N. Engl. J. Med. 303,183 -188.[Abstract]
Brookmeyer, R., and Crowley, J. (1982) A confidence interval for the median survival time. Biometrics 38, 29-41.[CrossRef][ISI]
Cairncross, J.G., Ueki, K., Zlatescu, M.C., Lisle, D.K.,
Finelstein, D.M., Hammond, R.R., Silver, J.S., Stark, P.C., Macdonald, D.R.,
Ino, Y., Ramsay, D.A., and Louis, D.N. (1998) Specific genetic
predictors of chemotherapeutic response and survival in patients with
anaplastic oligodendrogliomas. J. Natl. Cancer Inst.
90,1473
-1479.
Castellino, R.C., Elion, G.B., Keir, S.T., Houghton, P.J., Johnson, S.P., Bigner, D.D., and Friedman, H.S. (2000) Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts [erratum in Cancer Chemother. Pharmacol. 46, 84, 2000]. Cancer Chemother. Pharmacol. 45,345 -349.[CrossRef][ISI][Medline]
Chang, C.H., Horton, J., Schoenfeld, D., Salazer, O., Perez-Tamayo, R., Kramer, S., Weinstein, A., Nelson, J.S., and Tsukada, Y. (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52,997 -1007.[CrossRef][ISI][Medline]
Coggins, C.A., Elion, G.B., Houghton, P.J., Hare, C.B., Keir, S., Colvin, O.M., Bigner, D.D., and Friedman, H.S. (1998) Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother. Pharmacol. 41,485 -490.[CrossRef][ISI][Medline]
Deutsch, M., Green, S.B., Strike, T.A., Burger, P.C., Robertson, J.T., Selker, R.G., Shapiro, W.R., Mealey, J., Jr., Ransohoff, J., 2nd, and Paoletti, P. (1989) Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 16,1389 -1396.[ISI][Medline]
Fine, H.A., Dear, K.B., Loeffler, J.S., Black, P.M., and Canellos, G.P. (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71,2585 -2597.[CrossRef][ISI][Medline]
Friedman, H.S., Petros, W.P., Friedman, A.H, Schaaf, L.J., Kerby,
T., Lawyer, J., Parry, M., Houghton, P.J., Lovell, S., Rasheed, K., Cloughesy,
T., Stewart, E.S., Colvin, O.M., Provenzale, J.M., McLendon, R.E., Bigner,
D.D., Cokgor, I., Haglund, M., Rich, J., Ashley, D., Malczyn, J., Elfring,
G.L., and Miller, L.L. (1999) Irinotecan therapy in adults with
recurrent or progressive malignant glioma. J. Clin.
Oncol. 17,1516
-1525.
Friedman, H.S., Kerby, T., and Calvert, H. (2000)
Temozolomide and treatment of malignant glioma. Clin. Cancer
Res. 6,2585
-2597.
Green, S.B., Byar, D.P., Walker, M.D., Pistenmaa, D.A., Alexander E., Jr., Batzdorf, U., Brooks, W.H., Hunt, W.E., Mealey, J., Jr., Odom, G.L., Paoletti, P., Ransohoff, J., 2nd, Robertson, J.T., Selker, R.G., Shapiro, W.R., Smith, K.R., Jr., Wilson, C.B., and Strike, T.A. (1983) Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat. Rep. 67,121 -132.[ISI][Medline]
Grossman, S.A., O'Neill, A., Grunnet, M., Pearlman, J.L., Wagner,
H., Gilbert, M., Newton, H.B., Hellman, R., and Eastern Cooperative Oncology
Group (2003) Phase III study comparing three cycles of infusional
carmustine and cisplatin followed by radiation therapy with radiation therapy
and concurrent carmustine in patients with newly diagnosed supratentorial
glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394.
J. Clin. Oncol. 21,1485
-1491.
Grossman S.A., Wharam M., Sheidler V., Kleinberg, L., Zeltzman, M.,
Yue, N., and Piantadosi, S. (1997) Phase II study of continuous
infusion carmustine and cisplatin followed by cranial irradiation in adults
with newly diagnosed high-grade astrocytoma. J. Clin.
Oncol. 15,2596
-2603.
Hare, C.B., Elion, G.B., Houghton, P.J., Houghton, J.A., Keir, S., Marcelli, S.L., Bigner, D.D., and Friedman, H.S. (1997) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol. 39,187 -191.[CrossRef][ISI][Medline]
Houghton, P.J., Cheshire, P.J., Hallman, J.D., 2nd, Lutz, L., Friedman, H.S., Danks, M.K., and Houghton, J.A. (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36,393 -403.[ISI][Medline]
Ino, Y., Betensky, R.A., Zlatescu, M.C., Sasaki, H., Macdonald,
D.R., Stemmer-Rachmanimov, A.O., Ramsay, D.A., Cairncross, J.G., and Louis,
D.N. (2001) Molecular subtypes of anaplastic oligodendroglioma:
Implications for patient management at diagnosis. Clin. Cancer
Res. 7,839
-845.
Klein J.P. (1991) Small sample moments of some estimators of the variance of the Kaplan-Meier and Nelson-Aalen estimators. Scand. J. Stat. 18,333 -340.
Kristof, R.A., Neuloh, G., Hans, V., Deckert, M., Urbach, H., Schlegel, U., Simon, M., and Schramm, J. (2002) Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III. J. Neurooncol. 59,231 -237.[CrossRef][Medline]
Levin, V.A., Wara, W.M., Davis, R.L., Vestnys, P., Resser, K.J., Yatsko, K., Nutik, S., Gutin, P.H., and Wilson, C.B. (1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J. Neurosurg. 63,218 -223.[ISI][Medline]
Levin, V.A., Silver, P., Hannigan, J., Wara, W.M., Gutin, P.H., Davis, R.L., and Wilson, C.B. (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18,321 -324.[ISI][Medline]
Medical Research Council Brain Tumor Working Party
(2001) Randomized trial of procarbazine, lomustine, and
vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical
Research Council trial. J. Clin. Oncol.
19,509
-518.
NCI. National Cancer Institute, Cancer Therapy Evaluation Program. Common Toxicity Criteria—Version 2.0, published April 30, 1999. Cited January 5, 2004. Available at https://webapps.ctep.nci.nih.gov/ctcv2/plsql/ctc000w$.startup.
Patel, V.J., Elion, G.B., Houghton, P.J., Keir, S., Pegg, A.E.,
Johnson, S.P., Dolan, M.E., Bigner, D.D., and Friedman, H.S.
(2000) Schedule-dependent activity of temozolomide plus CPT-11
against a human central nervous system tumor-derived xenograft.
Clin. Cancer Res. 6,4154
-4157.
Pourquier, P., Waltman, J.L., Urasaki, Y., Loktionova, N.A., Pegg,
A.E., Nitiss, J.L., and Pommier, Y. (2001) Topoisomerase
I-mediated cytotoxicity of
N-methyl-N'-nitro-N'-nitrosoguanidine: Trapping of
topoisomerase I by the O6-methylguanine. Cancer
Res. 61,53
-58.
Quinn, J.A., Reardon, D.A., Friedman, A.H., Rich, J.N., Sampson, J.H., Vredenburgh, J., Gururangan, S., Provenzale, J.M., Walker, A., Schweitzer, H., Bigner, D.D., Tourt-Uhlig, S., Herndon, J.E., II, Affronti, M.L., Jackson, S., Allen, D., Zeigler, K., Bohlin, C., Lentz, C., and Friedman, H.S. (2004) Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro-oncol. 6,145 -153.[Abstract]
Rajkumar, S.V., Buckner, J.C., Schomberg P.J., Pitot, H.C., 4th, Ingle, J.N., and Cascino, T.L. (1999) Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas. Neurosurgery 44,67 -73.[CrossRef][ISI][Medline]
Shapiro, W.R., Green, S.B., Burger, P.C., Mahaley, M.S., Jr., Selker, R.G., VanGilder, J.C., Roberston, J.T., Ransohoff, J., Mealey, J., Jr., Strike, T.A., and Pistenmaa, D.A. (1989) Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Trial 8001. J. Neurosurg. 71,1 -9.[ISI][Medline]
Slichenmyer, W.J., Rowinsky, E.K., Grochow, L.B., Kaufmann, S.H., and Donehower, R.C. (1994) Camptothecin analogues: Studies from the Johns Hopkins Oncology Center. Cancer Chemother. Pharmacol. 34,S53 -S57 (suppl.).
Smith, J.S., Perry, A., Borell, T.J., Lee, H.K., O'Fallon, J.,
Hosek, S.M., Kimmel, D., Yates, A., Burger, P.C., Scheithauer, B.W., and
Jenkins, R.B. (2000) Alterations of chromosome arms 1p and 19q as
predictors of survival in oligodendrogliomas, astrocytomas, and mixed
oligoastrocytomas. J. Clin. Oncol.
18,636
-645.
Stenning, S.P., Freedman, L.S., and Bleehen, N.M. (1987) An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br. J. Cancer 56,89 -90.[ISI][Medline]
Stewart, L.A., and Glioma Meta-analysis Trialists (GMT) Group (2002) Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359,1011 -1018.[CrossRef][ISI][Medline]
Stupp, R., Dietrich, P.-Y., Ostermann Kraljevic, S., Pica, A.,
Maillard, I., Maeder, P., Meuli, R., Janzer, R., Pizzolato, G., Miralbell, R.,
Porchet, F., Regli, L., de Tribolet, N., Mirimanoff, R.O., and Leyvraz, S.
(2002) Promising survival for patients with newly diagnosed
glioblastoma multiforme treated with concomitant radiation plus temozolomide
followed by adjuvant temozolomide. J. Clin. Oncol.
20,1375
-1382.
Walker, M.D., Alexander, E., Jr., Hunt, W.E., MacCarty, C.S., Mahaley, M.S., Jr., Mealey, J., Jr., Norrell, H.A., Owens, G., Ransohoff, J., Wilson, C.B., Gehan, E.A., and Strike, T.A. (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49,333 -343.[ISI][Medline]
Wong, E.T., Hess, K.R., Gleason, M.J., Jaeckle, K.A., Kyritisis,
A.P., Prados, M.D., Levin, V.A., and Yung, W.K. (1999) Outcomes
and prognostic factors in recurrent glioma patients enrolled onto phase II
clinical trials. J. Clin. Oncol.
17,2572
-2578.
This article has been cited by other articles:
|
|
 |
|
  V. K. Puduvalli, P. Giglio, M. D. Groves, K. R. Hess, M. R. Gilbert, S. Mahankali, E. F. Jackson, V. A. Levin, C. A. Conrad, S. H. Hsu, et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neuro-oncol, April 1, 2008; 10(2): 216 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Lustig, T. Mikkelsen, G. Lesser, S. Grossman, X. Ye, S. Desideri, J. Fisher, J. Wright, and the New Approaches to Brain Tumor Therapy CNS Cons Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease Neuro-oncol, January 1, 2008; 10(6): 1004 - 1009. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
